Comparison · NCT00939770-c5dafd86
Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID vs Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID: Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID vs Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID: Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib. Trial comparisons, record NCT00939770-c5dafd86. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00939770-c5dafd86
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0714 | 0.0127 | 0.315 | wilson | |
| Risk in group 2 | 0.7 | 0.397 | 0.892 | wilson | |
| Risk difference, group 1 minus group 2 | -0.629 | -0.83 | -0.24 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.102 | 0.0148 | 0.704 | log | |
| Odds ratio, group 1 over group 2 | 0.033 | 0.00287 | 0.379 | log | |
| Number needed to treat, for one fewer participant with the outcome on Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID than on Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID | 1.59 | 1.21 | 4.17 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID | Part B: Patients with ALK+ relapsed/refractory neuroblastoma | 1 | 14 | OG000 |
| Group 2 | Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID | Part C: Patients with ALK+ relapsed/refractory ALCL | 7 | 10 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants (Relapsed or Refractory Neuroblastoma or Anaplastic Large Cell Lymphoma (ALCL)) With Response to Crizotinib
- Description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
- Time frame
- Up to 8 years
- Population
- Part B and Part C participants with relapsed or refractory neuroblastoma or anaplastic large cell lymphoma (ALCL)
Source ClinicalTrials.gov
Trial
- Title
- Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
- NCT number
- NCT00939770
- Phases
- PHASE1, PHASE2
- Conditions
Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
- Interventions
- Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
- Lead sponsor
- Children's Oncology Group
- Results first posted
- 2020-05-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00939770?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00939770-c5dafd86